-
Patent Agency Ranking
公开(公告)号：US11319344B2
公开(公告)日：2022-05-03
申请号：US15550766
申请日：2016-02-15
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Yaw Sing Tan , Christopher John Brown , Chandra S. Verma , Fernando Jose Ferrer Gago , David P. Lane , Thomas Joseph
Abstract: The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaa1EY-WXaa3LLXaa2, where Xaa1 is (R)-2-(7′-octenyl)alanine or derivative thereof, or is (R)-2-(4′-pentenyl)alanine or derivative thereof; and Xaa2 and Xaa3 are independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaa1EYW Xaa3LLXaa2ENXaa5, wherein Xaa1 and Xaa3 are any type of amino acid or modified amino acid; Xaa2 is S, or P, or (S)-2-(4′-pentenyl)alanine or a derivative of (S)-2-(4′-pentenyl)alanine; and wherein Xaa5 is F or Y.
-
公开(公告)号：US20160046672A1
公开(公告)日：2016-02-18
申请号：US14778761
申请日：2014-02-28
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Christopher John Brown , David Philip Lane , Soo Tng Quah , Dilraj Lama , Chandra Shekhar Verma
IPC: C07K7/08
CPC classification number: C07K7/08 , A61K38/00 , C07K14/4705
Abstract: The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides.
Abstract translation: 本发明涉及与人eIF4G相关并结合eIF4E的交联肽，其用途和包含该肽的药物组合物。
-
公开(公告)号：US09533023B2
公开(公告)日：2017-01-03
申请号：US14675675
申请日：2015-03-31
Applicant: Agency for Science, Technology and Research
Inventor： Christopher John Brown , Cheng San Brian Chia
CPC classification number: A61K38/1709 , A61K38/00 , C07K7/08 , C07K14/4705 , C07K2319/10
Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
Abstract translation: 本发明涉及修饰的eIF4G1肽，其用途和包含经修饰的eIF4G1肽的药物组合物。
-
公开(公告)号：US20220242906A1
公开(公告)日：2022-08-04
申请号：US17436118
申请日：2020-03-30
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Simon Ng , Christopher John Brown
Abstract: A peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX1GX2X3X4X5C (SEQ ID NO: 1), where X1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L), X2 and X3 is an amino acid selected from the group consisting of phenylalanine (F), modified phenylalanine and tyrosine (Y), X4 and X5 is any amino acid, wherein the two cysteine residues are joined by a disulphide bond. Further, pharmaceutical compositions and uses of the peptide, and pharmaceutical compositions are provided.
-
公开(公告)号：US20150246946A1
公开(公告)日：2015-09-03
申请号：US14432729
申请日：2013-10-01
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Thomas Leonard Joseph , Chandra Shekhar Verma , David Phillip Lane , Christopher John Brown
CPC classification number: C07K7/06 , A61K38/00 , A61K38/08 , A61K38/10 , A61K45/06 , C07K7/08 , A61K2300/00
Abstract: By using a phage display derived peptide as an initial template, compounds have been developed that are highly specific against Mdm2/Mdm4. These compounds exhibit greater potency in p53 activation and protein-protein interaction assays than a compound derived from the p53 wild-type sequence. Unlike nutlin, a small molecule inhibitor of Mdm2/Mdm4, the phage derived compounds can arrest cells resistant to p53 induced apoptosis over a wide concentration range without cellular toxicity, suggesting they are highly suitable for cyclotherapy.
Abstract translation: 通过使用噬菌体展示衍生肽作为初始模板，开发了对Mdm2 / Mdm4具有高度特异性的化合物。 与来自p53野生型序列的化合物相比，这些化合物在p53活化和蛋白质 - 蛋白质相互作用测定中表现出更大的效力。 与Mdm2 / Mdm4的小分子抑制剂nutlin不同，噬菌体衍生的化合物可以在宽的浓度范围内阻止对p53诱导的细胞凋亡的细胞，而无细胞毒性，表明它们非常适合于环境疗法。
-
-
-
-
Search Results
5
records
(took 0.016 seconds)
